These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11600616)

  • 1. Correction: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
    Pestalozzi BC
    J Clin Oncol; 2001 Oct; 19(20):4091. PubMed ID: 11600616
    [No Abstract]   [Full Text] [Related]  

  • 2. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
    Baculi RH; Suki S; Nisbett J; Leeds N; Groves M
    J Clin Oncol; 2001 Jul; 19(13):3297-8. PubMed ID: 11432901
    [No Abstract]   [Full Text] [Related]  

  • 3. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
    Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.
    Laufman LR; Forsthoefel KF
    Clin Breast Cancer; 2001 Oct; 2(3):235. PubMed ID: 11899418
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab for breast cancer-related carcinomatous meningitis.
    Robins HI; Liu G; Hayes L; Mehta M
    Clin Breast Cancer; 2002 Jan; 2(4):316. PubMed ID: 11899365
    [No Abstract]   [Full Text] [Related]  

  • 7. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
    Platini C; Long J; Walter S
    Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
    [No Abstract]   [Full Text] [Related]  

  • 8. [Trastuzumab in metastatic breast carcinoma].
    Susnjar S; Bosnjak S; Radulovic S
    Srp Arh Celok Lek; 2001; 129(5-6):147-52. PubMed ID: 11797464
    [No Abstract]   [Full Text] [Related]  

  • 9. Meningeal carcinomatosis in HER2-overexpressing breast cancers.
    Bidard FC; Guilhaume MN; Gauthier H; Cottu PH; Diéras V; Pierga JY
    J Neurooncol; 2009 Jun; 93(2):287-8. PubMed ID: 19139826
    [No Abstract]   [Full Text] [Related]  

  • 10. [Trastuzumab and blood-brain barrier].
    Platini C
    Bull Cancer; 2007 Oct; 94(10):857-9. PubMed ID: 17964978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of advanced breast cancer with meningeal carcinomas and orbital metastasis successfully treated with multi-disciplinary therapy].
    Sakurai K; Amano S; Enomoto K; Matsuo S
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1913-5. PubMed ID: 17212145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.
    Mir O; Ropert S; Alexandre J; Lemare F; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1978-80. PubMed ID: 18845838
    [No Abstract]   [Full Text] [Related]  

  • 13. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15-3 measurement in cerebrospinal fluid].
    Gauchez AS; Pez E; Boutonnat J; Bourre JC; Pelletier L; Payan R; Mousseau M
    Ann Biol Clin (Paris); 2007; 65(6):653-8. PubMed ID: 18039611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Images in clinical medicine. Meningeal carcinomatosis in breast cancer.
    Ornstein DL; Frederickson K
    N Engl J Med; 2000 Apr; 342(15):1093. PubMed ID: 10760309
    [No Abstract]   [Full Text] [Related]  

  • 16. Intrathecal trastuzumab: dose matters.
    Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
    Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
    [No Abstract]   [Full Text] [Related]  

  • 17. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 18. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
    Offerhaus L
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival after brain metastases from breast cancer in the trastuzumab era.
    Kirsch DG; Ledezma CJ; Mathews CS; Bhan AK; Ancukiewicz M; Hochberg FH; Loeffler JS
    J Clin Oncol; 2005 Mar; 23(9):2114-6; author reply 2116-7. PubMed ID: 15774813
    [No Abstract]   [Full Text] [Related]  

  • 20. Brain metastases in patients receiving trastuzumab for breast cancer.
    Salmaggi A; Silvani A; Boiardi A
    Neurol Sci; 2007 Mar; 28(1):1. PubMed ID: 17385088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.